-
公开(公告)号:US5829436A
公开(公告)日:1998-11-03
申请号:US789551
申请日:1997-01-27
CPC分类号: A61K51/1206 , A61B5/0813 , A61B6/4258 , A61K2123/00
摘要: A method of diagnosing a patient is carried out by delivering an aerosolized dose of a radioactive formulation to a patient and making a ventilation image of radioactive material deposited in the lung. This image is compared with a separately generated image (perfusion image) taken after injecting radiolabled particles into the pulmonary arterial circulation. Devices, packaging and methodology for creating aerosols are provided which allow for efficient and repeatable delivery of radioaerosols to the lungs of a patient. Devices may be plug-in units or hand-held, self-contained units which are automatically actuated at the same release point in a patient's inspiratory flow cycle. The device is loaded with a container of a radioactive formulation such as .sup.99m Tc-labelled diethylene-triamine pentaacetic acid (DTPA). Actuation of the device forces the radioactive formulation through a porous membrane of the container which membrane has pores having a diameter in the range of about 0.25 to 6.0 microns. The container includes radioactive shielding in the form of a lead coating and/or a lead surrounding packet. The porous membrane is positioned in alignment with a surface of a channel through which a patient inhales air.
摘要翻译: 通过将放射性制剂的雾化剂量递送到患者并且放置在肺中的放射性物质的通风图像来进行诊断患者的方法。 将该图像与在肺动脉循环中注射放射性粒子后分离产生的图像(灌注图像)进行比较。 提供了用于产生气溶胶的装置,包装和方法,其允许放射性天然气对患者的肺的有效和可重复的递送。 设备可以是插入式单元或手持的独立单元,其在患者的吸气流循环中在相同的释放点自动启动。 该装置装载有放射性制剂的容器,例如99mTc标记的二亚乙基三胺五乙酸(DTPA)。 该装置的致动迫使放射性制剂通过容器的多孔膜,该膜具有直径在约0.25至6.0微米范围内的孔。 容器包括铅涂层和/或铅包围形式的放射性屏蔽。 多孔膜定位成与患者吸入空气的通道的表面对准。
-
2.
公开(公告)号:US07490603B2
公开(公告)日:2009-02-17
申请号:US11284579
申请日:2005-11-21
申请人: Igor Gonda , Reid M. Rubsamen , Stephen J. Farr
发明人: Igor Gonda , Reid M. Rubsamen , Stephen J. Farr
IPC分类号: A61M11/00
CPC分类号: A61K9/007 , A61J7/0418 , A61J7/0427 , A61J7/0445 , A61K9/0073 , A61K9/0075 , A61K38/28 , A61M11/001 , A61M15/00 , A61M15/0031 , A61M15/0045 , A61M15/0051 , A61M15/0065 , A61M15/0066 , A61M15/008 , A61M15/0085 , A61M15/009 , A61M16/142 , A61M2016/0021 , A61M2016/0036 , A61M2202/062 , A61M2202/064 , A61M2205/50 , A61M2205/8206
摘要: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release.
-
3.
公开(公告)号:US07021309B2
公开(公告)日:2006-04-04
申请号:US10682529
申请日:2003-10-08
申请人: Igor Gonda , Reid M. Rubsamen , Stephen J. Farr
发明人: Igor Gonda , Reid M. Rubsamen , Stephen J. Farr
IPC分类号: A61M11/00
CPC分类号: A61K9/007 , A61J7/0418 , A61J7/0427 , A61J7/0445 , A61K9/0073 , A61K9/0075 , A61K38/28 , A61M11/001 , A61M15/00 , A61M15/0031 , A61M15/0045 , A61M15/0051 , A61M15/0065 , A61M15/0066 , A61M15/008 , A61M15/0085 , A61M15/009 , A61M16/142 , A61M2016/0021 , A61M2016/0036 , A61M2202/062 , A61M2202/064 , A61M2205/50 , A61M2205/8206
摘要: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release.
-
公开(公告)号:US5941240A
公开(公告)日:1999-08-24
申请号:US160909
申请日:1998-09-25
申请人: Igor Gonda , Reid M. Rubsamen , Stephen J. Farr
发明人: Igor Gonda , Reid M. Rubsamen , Stephen J. Farr
CPC分类号: A61K9/007 , A61K38/28 , A61K9/0073 , A61M11/001 , A61M15/00 , A61M15/0031 , A61M15/0043 , A61M15/0045 , A61M15/0051 , A61M15/0066 , A61M15/008 , A61M16/142 , A61J7/0418 , A61J7/0427 , A61J7/0445 , A61M15/0085 , A61M15/009 , A61M2016/0021 , A61M2016/0036 , A61M2202/062 , A61M2202/064 , A61M2205/50 , A61M2205/8206 , Y10S514/866
摘要: Dosages of inhaled insulin are controlled within a narrow range by controlling the total volume of air inhaled by a patient. By repeatedly delivering aerosolized insulin with the same total inhaled volume of air, the amount of insulin delivered to the patient each time is consistent. A device for delivering insulin by inhalation is disclosed which device comprises a means for measuring inhaled volume and for halting inhalation at a pre-determined point. The device also comprises an adjustable means for applying various amounts of force to a container of formulation to expel different amounts of drug from the container based on the force applied.
-
公开(公告)号:US07278419B2
公开(公告)日:2007-10-09
申请号:US10768371
申请日:2004-01-30
申请人: Igor Gonda , Reid M. Rubsamen , Stephen J. Farr
发明人: Igor Gonda , Reid M. Rubsamen , Stephen J. Farr
IPC分类号: A61M11/00
CPC分类号: A61K9/007 , A61J7/0418 , A61J7/0427 , A61J7/0445 , A61K9/0073 , A61K9/0075 , A61K38/28 , A61M11/001 , A61M15/00 , A61M15/0031 , A61M15/0045 , A61M15/0051 , A61M15/0065 , A61M15/0066 , A61M15/008 , A61M15/0085 , A61M15/009 , A61M16/142 , A61M2016/0021 , A61M2016/0036 , A61M2202/062 , A61M2202/064 , A61M2205/50 , A61M2205/8206
摘要: The need for the delivery of insulin by injection can be reduced or eliminated by delivering aerosolized insulin. Repeatability of dosing is obtainable by using either regular insulin or monomeric insulin. When delivering insulin (not monomeric) by inhalation, the total inhaled volume should be about the same at each delivery to obtain repeatable results. The patient can be coached (by teaching) to inhale a given amount of air and can also be coached (by teaching) to inhale at a given flow rate. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. A dry powder or a liquid insulin formulation is delivered to the patient from a mechanical or electronic hand-held, self-contained device.
摘要翻译: 通过注射雾化胰岛素可以减少或消除通过注射输送胰岛素的需要。 给药的重复性可通过使用正常胰岛素或单体胰岛素获得。 当通过吸入输送胰岛素(非单体)时,每次输送时,总吸入体积应大致相同,以获得可重复的结果。 患者可以通过教学来吸引一定量的空气,也可以通过教导进行指导,以给定的流量进行吸气。 此外,通过使用单体胰岛素来增加血糖降低的速度。 输送到肺组织表面的胰岛素和单体胰岛素的颗粒将被吸收到循环系统中。 将干粉或液体胰岛素制剂从机械或电子手持式独立装置输送给患者。
-
6.
公开(公告)号:US06431166B1
公开(公告)日:2002-08-13
申请号:US09784861
申请日:2001-02-15
申请人: Igor Gonda , Reid M Rubsamen , Stephen J. Farr
发明人: Igor Gonda , Reid M Rubsamen , Stephen J. Farr
IPC分类号: A61M1100
摘要: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release.
-
7.
公开(公告)号:US6131567A
公开(公告)日:2000-10-17
申请号:US4756
申请日:1998-01-08
申请人: Igor Gonda , Reid M. Rubsamen , Stephen J. Farr
发明人: Igor Gonda , Reid M. Rubsamen , Stephen J. Farr
IPC分类号: A61K9/12 , A61J7/04 , A61K9/00 , A61K9/72 , A61K38/28 , A61M15/00 , A61M16/00 , A61M16/14 , A61P3/10 , A61P43/00 , A61M11/00
CPC分类号: A61K9/0075 , A61K38/28 , A61K9/007 , A61K9/0073 , A61M11/001 , A61M15/00 , A61M15/0031 , A61M15/0065 , A61M15/008 , A61M16/142 , A61J7/0418 , A61J7/0427 , A61J7/0445 , A61M15/0051 , A61M15/0066 , A61M15/0085 , A61M15/009 , A61M2016/0021 , A61M2202/062 , A61M2202/064 , A61M2205/8206
摘要: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release.
-
公开(公告)号:US5884620A
公开(公告)日:1999-03-23
申请号:US846243
申请日:1997-04-25
申请人: Igor Gonda , Reid M. Rubsamen , Stephen J. Farr
发明人: Igor Gonda , Reid M. Rubsamen , Stephen J. Farr
CPC分类号: A61K9/007 , A61K38/28 , A61K9/0073 , A61M11/001 , A61M15/00 , A61M15/0031 , A61M15/0043 , A61M15/0045 , A61M15/0051 , A61M15/0066 , A61M15/008 , A61M16/142 , A61J7/0418 , A61J7/0427 , A61J7/0445 , A61M15/0085 , A61M15/009 , A61M2016/0021 , A61M2016/0036 , A61M2202/062 , A61M2202/064 , A61M2205/50 , A61M2205/8206 , Y10S514/866
摘要: Dosages of inhaled insulin are controlled within a narrow range by controlling the total volume of air inhaled by a patient. By repeatedly delivering aerosolized insulin with the same total inhaled volume of air, the amount of insulin delivered to the patient each time is consistent. A device for delivering insulin by inhalation is disclosed which device comprises a means for measuring inhaled volume and for halting inhalation at a pre-determined point. The device also comprises an adjustable means for applying various amounts of force to a container of formulation to expel different amounts of drug from the container based on the force applied.
-
公开(公告)号:US07448375B2
公开(公告)日:2008-11-11
申请号:US11130986
申请日:2005-05-17
申请人: Igor Gonda , Reid M. Rubsamen , Stephen J. Farr
发明人: Igor Gonda , Reid M. Rubsamen , Stephen J. Farr
IPC分类号: A61M11/00
CPC分类号: A61M15/0045 , A61M11/001 , A61M15/0043 , A61M15/0051 , A61M15/0066 , A61M15/008 , A61M15/0081 , A61M15/0083
摘要: Dosages of inhaled insulin are controlled within a narrow range by controlling the total volume of air inhaled by a patient. By repeatedly delivering aerosolized insulin with the same total inhaled volume of air, the amount of insulin delivered to the patient each time is consistent. A device for delivering insulin by inhalation is disclosed which device comprises a means for measuring inhaled volume and for halting inhalation at a pre-determined point. The device also comprises an adjustable means for applying various amounts of force to a container of formulation to expel different amounts of drug from the container based on the force applied.
摘要翻译: 通过控制患者吸入的空气的总体积,将吸入胰岛素的剂量控制在狭窄的范围内。 通过以相同的总吸入体积的空气重复递送雾化胰岛素,每次输送给患者的胰岛素量是一致的。 公开了一种用于通过吸入递送胰岛素的装置,该装置包括用于测量吸入体积并在预定点停止吸入的装置。 该装置还包括可调节装置,用于根据施加的力将不同量的力施加到制剂容器以从容器中排出不同量的药物。
-
10.
公开(公告)号:US06431167B1
公开(公告)日:2002-08-13
申请号:US09975085
申请日:2001-10-09
申请人: Igor Gonda , Reid M. Rubsamen , Stephen J. Farr
发明人: Igor Gonda , Reid M. Rubsamen , Stephen J. Farr
IPC分类号: A61M1100
CPC分类号: A61K9/007 , A61J7/0418 , A61J7/0427 , A61J7/0445 , A61K9/0073 , A61K9/0075 , A61K38/28 , A61M11/001 , A61M15/00 , A61M15/0031 , A61M15/0045 , A61M15/0051 , A61M15/0065 , A61M15/0066 , A61M15/008 , A61M15/0085 , A61M15/009 , A61M16/142 , A61M2016/0021 , A61M2016/0036 , A61M2202/062 , A61M2202/064 , A61M2205/50 , A61M2205/8206
摘要: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release.
-
-
-
-
-
-
-
-
-